Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005962 · ClinicalTrials.gov registry record · Phase 2
Comparison of Three Treatment Regimens in Treating Patients With Relapsed or Refractory Acute Myelogenous Leukemia
A Phase 2 study, sponsored by Eastern Cooperative Oncology Group.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00005962 is a Phase 2 study that has completed, run by Eastern Cooperative Oncology Group.
The verdict
NCT00005962, a Phase 2 study, has completed, sponsored by Eastern Cooperative Oncology Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies such as gemtuzumab ozogamicin can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Combining more than one drug or combining monoclonal antibody with chemotherapy may kill more cancer cells. It is not yet known which treatment regimen is more effective for acute myelogenous leukemia. PURPOSE: Randomized phase II trial to compare the effectiveness of three treatment regimens in treating patients who have relapsed or refractory acute myelogenous leukemia.
Interventions
- DRUG cyclophosphamide
- DRUG cytarabine
- DRUG gemtuzumab ozogamicin
- BIOLOGICAL sargramostim
- DRUG liposomal daunorubicin citrate
Trial Details
| Field | Value |
|---|---|
| Start Date | 2000-10-04 |
| Est. Completion | 2007-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00005962
The ClinicalTrials.gov registry entry for NCT00005962 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Eastern Cooperative Oncology Group, which has 141 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00005962 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00005962 about?
NCT00005962 is a clinical study titled "Comparison of Three Treatment Regimens in Treating Patients With Relapsed or Refractory Acute Myelogenous Leukemia". RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies such as gemtuzumab ozogamicin can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Combini...
What is the current status of trial NCT00005962?
This trial is currently completed. It is a Phase 2 study. The study started on 2000-10-04. Estimated completion is 2007-06.
What interventions are being tested in trial NCT00005962?
The interventions under investigation include: cyclophosphamide (DRUG), cytarabine (DRUG), gemtuzumab ozogamicin (DRUG), sargramostim (BIOLOGICAL), liposomal daunorubicin citrate (DRUG).
Who is sponsoring clinical trial NCT00005962?
This trial is sponsored by Eastern Cooperative Oncology Group, which has 141 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.